公司資料
Olema Pharmaceuticals, Inc. 股價、新聞與催化劑
- 股票代碼:
- OLMA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
10.77 USD (+1.32%)
收盤價
最後更新: 2026年8月17日
934M USD
市值
股價為何變動
As of Aug 17, 2026, OLMA closed up 1.32% at $10.77. No new same-company headline was identified in the current news window.
公司概覽
Endocrine-Driven Cancer Company
Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer.
Palazestrant
Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer.
OP-3136
OP-3136 is an oral KAT6 inhibitor intended to complement endocrine therapy and address transcriptional drivers of resistance.
未來催化劑
- Initiation of the Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026.
- Topline results from the Phase 3 OPERA-01 palazestrant study in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。